Are We Treating Heart Disease 30 Years Too Late? ApoB, LDL & Statins Explained | Dayspring & Soffer

Episode Overview

• Host Simon Hill (co-founder of 38TERA, Scientific Advisory Board member for IM8) sits down with lipid experts Dr. Thomas Dayspring (Master of the National Lipid Association) and Dr. Daniel Soffer (cardiologist, MNLA, and co-author of the 2026 Dyslipidemia Guidelines) to explore how to assess, manage, and prevent atherosclerosis before a major cardiovascular event ever occurs.
• The discussion traces the biology of plaque formation (atherogenesis), why age-adjusted cardiovascular mortality has fallen by over 80% since 1970, and the vital distinction between ApoB as the "necessary substrate" for plaque versus the metabolic and lifestyle triggers that accelerate disease.
• A major focus is unpacking the newly released 2026 Dyslipidemia Guidelines, which introduce the 30-to-79-year-old PREVENT risk calculator, incorporate 10- and 30-year risk horizons, add kidney function and ZIP code as risk factors, and clarify how to use "risk-enhancing factors" and Coronary CT Angiography (CCTA) to guide early treatment decisions.
• The guests compare the efficacy, mechanisms, and side-effect profiles of modern lipid-lowering therapies—including statins, ezetimibe, PCSK9 inhibitors (injectable and newly approved oral options), and bempedoic acid—while sharing their personal regimens and debating how aggressively to treat young adults with elevated ApoB but zero visible plaque.

Key Concepts

• The Mechanism of Atherogenesis and Ubiquity of Plaque: Atherosclerosis begins when cholesterol-carrying ApoB particles penetrate the endothelium (artery wall) and become trapped in the sub-endothelial glycoprotein matrix. Resident white blood cells consume these particles, transforming into "foam cells" that secrete inflammatory cytokines and proteases, recruiting more white blood cells and remodeling the artery wall. While plaque buildup is virtually ubiquitous in humans on autopsy, the clinical goal is preventing Major Adverse Cardiovascular Events (MACE: heart attacks, strokes, stents, bypass, or angina).
• ApoB as "Necessary Substrate" vs. Multi-Factor Causality: Dr. Dayspring emphasizes that ApoB is the sine qua non of atherosclerosis—without cholesterol-carrying ApoB particles entering the artery wall, plaque cannot form, regardless of how many other risk factors exist. Dr. Soffer adds nuance by framing ApoB as the "necessary substrate" rather than the sole "cause," noting that endothelial permeability and sub-endothelial retention are heavily influenced by blood pressure, insulin sensitivity, smoking, and genetics. Because atherogenesis has many moving parts, someone can theoretically live to 120 with an untreated LDL-C of 300 mg/dL without an event, while Tsimane hunter-gatherers in Bolivia remain free of atherosclerosis with moderate LDL-C levels (50–100 mg/dL) despite high parasitic inflammation. However, both doctors agree that in 100% of people who do develop significant atherosclerosis, lowering ApoB/LDL-C is the primary target of therapy.
• Physiological LDL-C Levels and "LDL-C Years": Extremely low LDL-C and ApoB levels (20 to 40 mg/dL, as seen in newborns or individuals with genetic hypobetalipoproteinemia) are completely physiological; they do not impair brain development, adrenal function, or gonadal hormone production. To estimate cumulative lifetime plaque exposure, clinicians use "LDL-C Years" (or ApoB Years), calculated by multiplying a patient's age by their LDL-C in mg/dL. Reaching a product of roughly 5,000 indicates a plaque burden that places the patient at definite risk for clinical events.
• Lifestyle vs. Genetic Hazard Ratios: Aside from rare monogenic disorders like Familial Hypercholesterolemia (FH, affecting ~1 in 300 people), single gene variants have a relatively weak impact on cardiovascular risk. Fewer than five places on the genome carry variants with major independent impact, and the worst single gene variant has a Hazard Ratio (HR) of less than 1.5 (a <50% risk increase). Conversely, high blood pressure, smoking, and diabetes each carry an independent HR of 2 to 4 (a 200% to 400% risk increase). Inheriting 10 to 1,000 minor variants creates "Polygenic Risk" ("death by a thousand paper cuts"), though Dr. Soffer notes that Polygenic Risk Scores (PRS) have not yet changed his clinical management of patients.
• Redefining Prevention Stages: Traditional guidelines divide patients into Secondary Prevention (those who have suffered a heart attack, stroke, revascularization, or peripheral artery amputation) and Primary Prevention (everyone else). Dr. Soffer points out the absurdity of lumping a healthy 25-year-old marathon runner into the same "primary prevention" bucket as a 65-year-old diabetic, hypertensive smoker with a Coronary Artery Calcium (CAC) score of 3,000. He categorizes plaque discovered on imaging prior to an event as "subclinical atherosclerosis," whereas Dr. Dayspring prefers to classify visible subclinical plaque as Secondary Prevention (reserving "Tertiary Prevention" for post-event care and "Primordial Prevention" for maintaining pristine arteries from birth).
• The 2026 Dyslipidemia Guidelines & PREVENT Calculator: The updated guidelines designate five groups for Class 1 ("should do") pharmacologic LDL-lowering therapy: secondary prevention, severe hypercholesterolemia (FH), diabetes, HIV, and Chronic Kidney Disease (Stages 3 or 4). For everyone else, the guidelines introduce the PREVENT calculator, which expands testing to ages 30–79, calculates both 10-year and 30-year risk, and integrates kidney function and ZIP code (a proxy for socioeconomic stress). For patients with low calculated risk, clinicians look at "risk-enhancing factors" to justify therapy, including unexplained early family history, reproductive history (PCOS, preeclampsia, gestational diabetes, early menopause), autoimmune diseases (lupus, psoriasis, vasculitis, scleroderma), high-risk ethnicity, and elevated biomarkers (ApoB, Lp(a), hs-CRP, triglycerides).
• Strengths and Limits of Vascular Imaging (CCTA vs. CIMT vs. CAC): When evaluating subclinical plaque, Dr. Soffer strongly prefers Coronary CT Angiography (CCTA) over Carotid Intima-Media Thickness (CIMT). CIMT has poor reproducibility across operators and only measures four pre-specified spots in the carotid artery—meaning a patient can receive a "normal" report (<1.5 mm thickness at those four sites) while harboring actual plaque millimeters away. Furthermore, while a zero CAC score rules out calcified plaque and a clean CCTA rules out gross visible coronary plaque, neither completely rules out microscopic sub-imaging plaque or intracranial (brain) atherosclerosis with "coronary sparing." Both doctors also explicitly note there are no clinical outcome trials proving the benefit of treating a 35-year-old with high ApoB, family history, and zero plaque on a CCTA; doing so relies on clinical extrapolation.
• Mechanisms and Hierarchy of Lipid-Lowering Drugs: Statins remain first-line therapy due to over 30 major cardiovascular outcome trials proving a linear relationship between LDL-C reduction and mortality reduction. While ~90% of reported statin side effects do not hold up against placebo in clinical trials, statins can enter all cells and cause true muscle symptoms (myalgia, via ~14 potential mechanisms identified by Dr. Paul Thompson, of which CoQ10 depletion is only one) or mild glycemic aggravation. Ezetimibe (which blocks gut cholesterol absorption) and PCSK9 inhibitors (which preserve liver LDL receptors and lower LDL-C/ApoB by 40–60%) are the best-tolerated drugs. Bempedoic acid is a prodrug activated by a liver-specific enzyme; because it cannot enter muscle cells, it causes no more muscle aches than placebo, though Dr. Soffer ranks it fourth because it only lowers LDL-C by ~20% at a high financial cost. Emerging options include a newly approved oral PCSK9 inhibitor, Inclisiran (a twice-yearly injection awaiting ORION-4 outcome data), and Verve (experimental gene-editing therapy).
• Sex-Specific Nuances and Lp(a): Women in their 30s at high cardiovascular risk can be treated early, pausing pharmacotherapy during conception, pregnancy, and lactation (historically used bile acid sequestrants only lower LDL-C by ~20% and cause severe GI distress and vitamin malabsorption). Intriguingly, a sub-analysis of the VESALIUS primary prevention trial (which lowered LDL-C to ~45 mg/dL using evolocumab) suggested that high blood PCSK9 levels are a stronger risk factor in women than men, and PCSK9 inhibitors may be more effective in women—a finding Dr. Dayspring notes is "hypothesis-generating." Regarding elevated Lp(a), until targeted drugs like pelacarsen report outcome data in the HORIZON trial, clinicians manage high Lp(a) by aggressively lowering overall ApoB (often to 50–60 mg/dL), even though it remains unproven whether the modest Lp(a) reduction seen with PCSK9 inhibitors independently drives event reduction.

Quotes

• At 0:04:01 - "When it consumes the ApoB-containing lipoprotein that's full of cholesterol, that's the initiation of atherosclerosis. And then you repeat that approximately a gazillion times throughout the course of a lifetime." - Dr. Daniel Soffer explaining the cellular initiation of arterial plaque via white blood cells turning into foam cells.
• At 0:10:21 - "High blood pressure, smoking, diabetes each have an independent hazard ratio for the outcome of cardiovascular—a bad outcome—that's on the order of 2 to 4. More than 200 to 400% increase in cardiovascular risk if you have one of those features. The hazard ratio of the worst single gene variant that is associated with atherosclerosis is less than 1.5." - Dr. Daniel Soffer contrasting the massive impact of metabolic and lifestyle factors against individual genetic variants.
• At 0:13:46 - "I think if we did 100% autopsies on everybody when they're croaking, you'd find atherosclerosis in virtually everybody, I think, for sure." - Dr. Thomas Dayspring highlighting that some degree of plaque is nearly universal in humans, making MACE prevention the true priority.
• At 0:18:21 - "Primary prevention is everyone else. The problem is that 'everyone else' includes the 25-year-old vegan marathon runner with four living grandparents and three great-grandparents who has no risk factors for heart disease, but it also includes the 65-year-old diabetic, obese, hypertensive smoker whose calcium score is 3,000." - Dr. Daniel Soffer illustrating why traditional "primary prevention" categories are too broad without subclinical imaging.
• At 0:20:40 - "The foundation of atherosclerosis management is eight things: it's eat healthy, exercise regularly, maintain a healthy body weight, don't smoke, optimize sleep and stress management, optimize blood pressure control, optimize blood sugar control and insulin sensitivity, and optimize whatever lipid metric Tom, you, and I decide is the best metric at the end of this conversation." - Dr. Daniel Soffer outlining the American Heart Association's Life's Essential 8.
• At 0:25:20 - "If you were covering the CCU that night, you would at least have three or four acute coronary syndrome admissions, a couple of them were in flagrant pulmonary edema, which I'm not so sure people even see anymore, where they're foaming at the mouth because they're in gross heart failure because there's so much of their myocardium was destroyed by an ischemic event." - Dr. Thomas Dayspring recounting the reality of hospital coronary care units in the 1970s before statins and modern lipid therapies existed.
• At 0:29:17 - "The age-adjusted mortality improvement from 1970 to the present has fallen by as much as 80 plus percent. And that is like fall off your chair—did he just say 80 plus percent? The answer is yes." - Dr. Daniel Soffer emphasizing the massive public health triumph of modern cardiovascular medicine and risk factor control.
• At 0:39:17 - "And even when you took an LDL-C from 70 down to 15, there was still further event reduction. So it's the multitude of those trials that provide the causality rationale behind this." - Dr. Thomas Dayspring citing clinical trial evidence showing a continuous, linear benefit to lowering LDL-C.
• At 0:40:11 - "They are the necessary substrate for atherosclerosis, absolutely. No ApoB, no LDL, there's no athero. But that's not the same as the cause. Like, a lot of things have to happen for athero to occur." - Dr. Daniel Soffer clarifying the distinction between the required building block of plaque (ApoB) and the complex vascular environment that triggers disease.
• At 0:41:12 - "You can definitely live to be 120 years old with an LDL cholesterol of 300 milligrams per deciliter and never having treated it and never have a cardiovascular event. But it's such a powerful indicator of risk when it's at the extremes." - Dr. Daniel Soffer explaining biological variability in plaque development while reinforcing why extreme lipid elevations still require treatment.
• At 0:43:30 - "Anybody who has atherosclerosis had to have an ApoB particle, as Dan said earlier, a gazillion of them over time, crashing the artery wall, depositing cholesterol. It's the only sine qua non for atherosclerosis. No cholesterol in the artery wall, no atherosclerosis. I don't care if you have 42 other risk factors—you smoke, hypertension, diabetes—no cholesterol in the artery wall, no atherosclerosis." - Dr. Thomas Dayspring defining ApoB as the one indispensable requirement for plaque formation.
• At 0:46:55 - "The proof is you don't need an LDL cholesterol of 120 to make your adrenal glands, your gonads work, or anything else, your brain to work." - Dr. Thomas Dayspring debunking myths that pharmacologically lowering blood LDL-C starves the brain or endocrine organs of necessary cholesterol.
• At 0:51:03 - "I don't kneejerk believe everybody has to have an ApoB under 50. I would do an evaluation when they came in, and if they're young and I don't find a bunch of other risk factors, no Lp(a), a terrible family history, I don't know that I'm going to put them on anything to make their ApoB 50. I'd be happy with a 70 or 80 in such a person." - Dr. Thomas Dayspring explaining that ultra-low ApoB targets (<50 mg/dL) are reserved for high-risk patients, not healthy young adults without risk enhancers.
• At 0:51:45 - "There were two concepts addressed in the guideline. One is, in general, lower for longer is better, just as a generality. And two, the intensity of LDL-lowering treatment should match the severity of the disease process that you're treating." - Dr. Daniel Soffer summarizing the two core guiding philosophies of the 2026 Dyslipidemia Guidelines.
• At 0:52:34 - "We have a new tool that's emerging and it's called LDL-C years—you can even extrapolate ApoB years. So you come in, you tell me your age, I see what your LDL cholesterol is, I multiply one by the other and I get a product there. And it looks like if that multiplication goes to around 5,000, and I'm talking milligrams per deciliter, not molar concentrations, then you are at—that's a plaque burden that you're at definitely a risk for something happening." - Dr. Thomas Dayspring providing a simple mathematical formula to estimate cumulative lifetime arterial exposure to cholesterol.
• At 1:29:39 - "Bempedoic acid only works in the liver; it doesn't inhibit cholesterol synthesis in any other organ in the body. There's a specific enzyme in the liver that changes a prodrug, bempedoic acid, to its active form, so no other cell can be affected by bempedoic acid." - Dr. Thomas Dayspring explaining why bempedoic acid does not cause muscle-related side effects in statin-intolerant patients.
• At 1:39:35 - "They start by getting their risk factors checked: their blood pressure checked, their waist size if they can't tell by looking in the mirror that they might have a problem there, and then they are going to go into their physician, they're going to probably get a standard lipid profile. All of the guidelines now say once in your life you have to have Lp(a) checked, so that's got to be on your to-do list. And if you're on Tom Dayspring's to-do list, while you're getting a lipid profile, get an ApoB also." - Dr. Thomas Dayspring giving listeners a concrete checklist for their next preventative doctor's visit.

Takeaways

• Build Your Foundation with "Life's Essential 8": Before relying solely on pharmacotherapy, audit and optimize the eight pillars of cardiovascular health: diet quality, regular exercise, healthy body weight/waist circumference, smoking cessation, sleep and stress management, blood pressure, blood sugar/insulin sensitivity, and blood lipids.
• Request an Expanded Baseline Lipid Panel: At your next physical, ask your doctor to add ApoB (to measure total atherogenic particle number) and a once-in-a-lifetime Lp(a) test alongside your standard lipid profile, blood pressure, and metabolic markers.
• Screen Children Early to Catch Genetic Risk: Follow pediatric guidelines by screening children's lipids between ages 9 and 11 (or as early as age 2 if there is a known family history of Familial Hypercholesterolemia or premature heart attacks), repeating the test between ages 17 and 21, and every 5 years thereafter.
• Calculate Your "LDL-C Years": Multiply your current age by your LDL-C (in mg/dL) to gauge your cumulative exposure; if your number is approaching 5,000, use this data point to initiate a proactive conversation with your physician about imaging or lipid-lowering therapy.
• Use the 2026 PREVENT Calculator and Audit "Risk Enhancers": If you are between ages 30 and 79, evaluate both your 10-year and 30-year cardiovascular risk using the new PREVENT calculator, and be sure to inform your doctor of non-traditional risk enhancers like PCOS, a history of preeclampsia or gestational diabetes, premature menopause, or autoimmune conditions (e.g., lupus, psoriasis).
• Choose CCTA Over CIMT for Subclinical Imaging: If you are in your 30s or 40s with elevated ApoB (e.g., 90–120 mg/dL) or a strong family history and want to check for existing plaque to guide treatment decisions, request a Coronary CT Angiogram (CCTA) rather than a Carotid IMT (CIMT) ultrasound, which can miss plaque outside its four pre-set measurement zones.
• Tailor Your ApoB Target to Your Total Risk Profile: Match treatment intensity to disease severity—if you are young with zero plaque, normal Lp(a), and no other risk factors, an ApoB of 70 to 80 mg/dL is generally sufficient; if you have subclinical plaque, strong family history, or elevated Lp(a), work with your doctor to push ApoB down to 50 to 60 mg/dL (or lower if you have had a prior cardiovascular event).
• Test Suspected Statin Muscle Pain with a Structured Re-Challenge: If you experience muscle aches on a statin, do not immediately abandon lipid therapy; work with your prescriber to pause the medication for 2 to 4 weeks to see if symptoms resolve, then re-challenge the drug (or try a lower dose combined with ezetimibe) to verify if the statin is truly the culprit.
• Leverage Non-Statin Alternatives When Necessary: If you have confirmed statin intolerance (like Dr. Dayspring), discuss combining liver-specific bempedoic acid, gut-targeted ezetimibe, or a PCSK9 inhibitor (either a bi-weekly injectable autopen or the newly approved daily oral pill taken fasting 30 minutes before food).
• Plan Medication Pauses Around Pregnancy: For women in their 30s with high genetic or metabolic risk, do not delay needed lipid-lowering treatment until after menopause; instead, treat ApoB early, safely pause systemic medications during conception, pregnancy, and lactation, and resume therapy afterward.